Arcadia Biosciences Q2 net loss widens
Arcadia Biosciences Q2 net loss widens
Overview
US wellness products producer's Q2 revenue was flat yr/yr due to inventory and shipping delays
Q2 net loss widened on unrealized losses and PIPE financing valuation loss
Company closed $4 mln private placement and ended Q2 with $4.2 mln in cash
Outlook
Company plans to introduce three additional new products in first half of 2027
Result Drivers
INVENTORY AND SHIPPING DELAYS - Co said flat Q2 sales were primarily due to low inventory balances and longer-than-expected shipping times
LOWER SG&A EXPENSES - SG&A fell by $1 mln in Q2, driven by lower employee costs and absence of M&A fees
Company press release: ID:nGNXl1XMB
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| $1.44 mln |
|
Q2 Loss Per Share |
| $2.09 |
|
Q2 Net Loss |
| $6.27 mln |
|
Q2 Operating Expenses |
| $1.94 mln |
|
Reuters Recommended Reads
Aug 13 - Lifeway Foods Q2 sales rise on volume growth
Aug 13 - BranchOut Food Q2 revenue hits record high on ingredient business growth
Aug 13 - Charlotte's Web Q2 revenue falls as retail exits weigh
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)